

AMENDMENTS TO LB892

Introduced by Judiciary.

1           1. On page 26, strike line 18 and insert the following new  
2 subdivisions:

3           "(27)(A) Xylazine or any of the substances listed below, including  
4 their salts, isomers, and salts of isomers whenever the existence of such  
5 salts, isomers, and salts of isomers is possible within the specific  
6 chemical designation:

- 7           (i) Xylazine-M (2,6-dimethylaniline);
- 8           (ii) Xylazine-M (N-thiourea-2,6-dimethylaniline);
- 9           (iii) Xylazine-M (sulfone-HO-) isomer 2;
- 10          (iv) Xylazine-M (HO-2,6-dimethylaniline isomer 1);
- 11          (v) Xylazine-M (HO-2,6-dimethylaniline isomer 2);
- 12          (vi) Xylazine M (oxo-);
- 13          (vii) Xylazine-M (HO-) isomer 1;
- 14          (viii) Xylazine-M (HO-) isomer 1 glucuronide;
- 15          (ix) Xylazine-M (HO-) isomer 2;
- 16          (x) Xylazine-M (HO-) isomer 2 glucuronide;
- 17          (xi) Xylazine-M (HO-oxo-) isomer 1;
- 18          (xii) Xylazine-M (HO-oxo-) isomer 1 glucuronide;
- 19          (xiii) Xylazine-M (HO-oxo-) isomer 2;
- 20          (xiv) Xylazine-M (HO-oxo-) isomer 2 glucuronide;
- 21          (xv) Xylazine-M (sulfone); and
- 22          (xvi) Xylazine-M (sulfone-HO-) isomer 1.

23          (B) This subdivision (27) shall not include xylazine when it is used  
24 in any of the following manners:

- 25          (i) Dispensing or prescribing for, or administering to, a nonhuman  
26 species a drug containing xylazine that has been approved by the United  
27 States Secretary of Health and Human Services under section 512 of the

1 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 360b, as such act existed  
2 on January 1, 2024;

3 (ii) Dispensing or prescribing for, or administering to, a nonhuman  
4 species that is permissible under section 512(a)(4) of the Federal Food,  
5 Drug, and Cosmetic Act, 21 U.S.C. 360b(a)(4), as such act existed on  
6 January 1, 2024;

7 (iii) The manufacturing, distribution, or use of xylazine as an  
8 active pharmaceutical ingredient for manufacturing an animal drug that  
9 has been approved under section 512 of the Federal Food, Drug, and  
10 Cosmetic Act, 21 U.S.C. 360b, or that has been issued an investigational  
11 use exemption under section 512(j) of the act, 21 U.S.C. 360b(j), as such  
12 act existed on January 1, 2024;

13 (iv) The manufacturing, distribution, or use of a xylazine bulk  
14 chemical for pharmaceutical compounding by licensed pharmacists or  
15 veterinarians for a nonhuman species in accordance with subdivision (B)  
16 (i) or (ii) of this subdivision (27); or

17 (v) Any other use approved or permissible under the Federal Food,  
18 Drug, and Cosmetic Act, when dispensed or prescribed for, or administered  
19 to, a nonhuman species in accordance with subdivision (B)(i) or (ii) of  
20 this subdivision (27)."